# FGD5

## Overview
FGD5 (FYVE, RhoGEF, and PH domain containing 5) is a gene that encodes a protein involved in intracellular signaling, particularly in the regulation of the actin cytoskeleton and cell morphology. The protein, characterized as a Rho-family guanine nucleotide exchange factor, contains FYVE, RhoGEF, and PH domains, which are essential for its function in endothelial cell processes such as angiogenesis and apoptosis (Chen2021FGD5). FGD5 plays a critical role in maintaining vascular integrity and function, influencing cellular movement and remodeling through its impact on cytoskeletal dynamics. Additionally, FGD5 is implicated in cancer progression, notably in gastric and breast cancers, where it affects tumor proliferation and metastasis through interactions with proteins like Sox2 and pathways such as EGFR-STAT3 (You2021Faciogenital; Valla2017FGD5). These interactions underscore its potential as a target for therapeutic interventions in oncology.

## Function
FGD5 (FYVE, RhoGEF, and PH domain containing 5) is a gene that encodes a protein involved in intracellular signaling pathways, particularly in the regulation of the actin cytoskeleton and cell shape. The protein contains FYVE, RhoGEF, and PH domains, which are crucial for its role in these processes. In healthy human cells, FGD5 is implicated in endothelial cell function and angiogenesis, influencing vascular development and maintenance (Chen2021FGD5).

FGD5 acts as a Rho-family guanine nucleotide exchange factor, which is known to regulate endothelial cell angiogenesis and apoptosis. This regulation is essential for maintaining the integrity and function of blood vessels. The protein's involvement in cytoskeletal dynamics suggests that it plays a role in normal cellular processes involving cellular movement and remodeling (Chen2021FGD5).

FGD5 is also involved in the regulation of the cytoskeleton, which is crucial for cellular movement and remodeling. This function is significant in processes such as cell migration and tissue development, highlighting its importance in maintaining normal physiological functions in the body (Chen2021FGD5).

## Clinical Significance
FGD5 has been implicated in various cancers due to its role in tumor proliferation and progression. In breast cancer, FGD5 amplification is associated with increased tumor proliferation, higher mitotic counts, and elevated Ki67 levels, which correlate with a poorer prognosis. This amplification is particularly significant in luminal breast cancer, where it is linked to a higher cumulative risk of death (Valla2017FGD5). 

In gastric cancer, FGD5 expression is elevated in advanced stages and is negatively correlated with patient survival. Knockdown of FGD5 in gastric cancer cell lines results in reduced cell proliferation, migration, and tumor growth, suggesting its role in cancer progression through the EGFR-STAT3 signaling pathway. FGD5 overexpression enhances EGFR stability, contributing to epithelial-mesenchymal transition and chemotherapy resistance (You2021Faciogenital; Chen2021FGD5).

FGD5 is also involved in the regulation of cancer stem cell-like traits in gastric cancer by interacting with Sox2, enhancing its stability and supporting traits associated with metastasis and drug resistance (You2021Faciogenital). These findings highlight FGD5 as a potential target for therapeutic strategies in cancer treatment.

## Interactions
FGD5 is involved in several interactions that influence cancer progression, particularly in gastric cancer. It interacts with the Sox2 protein, a critical regulator of cancer stem cell (CSC) progression. This interaction enhances Sox2 protein stability by decreasing its ubiquitination, thereby supporting CSC-like traits in gastric cancer cells (You2021Faciogenital). FGD5's role in stabilizing Sox2 is significant, as it contributes to the maintenance of CSC markers and traits, such as ALDH1 activity and spheroid-formation ability, which are associated with poor survival outcomes in gastric cancer patients (You2021Faciogenital).

FGD5 was initially identified in endothelial cells, where it is involved in neovessel fate and VEGF signaling, suggesting its participation in multiprotein complexes that affect endothelial cell function and angiogenesis (You2021Faciogenital). While the context does not provide specific details on FGD5's interactions with other proteins or nucleic acids beyond Sox2, its involvement in intracellular signaling pathways and interactions with small GTPases, particularly the Rho family, indicates its broader role in cytoskeletal organization and cell morphology. These interactions highlight FGD5's potential impact on tumor progression and metastasis in various cancers.


## References


[1. (You2021Faciogenital) Huaqiang You, Shan Gao, Xiaoping Xu, and Hong Yuan. Faciogenital dysplasia 5 confers the <scp>cancer stem cell</scp>‐like traits of gastric cancer cells through enhancing sox2 protein stability. Environmental Toxicology, 36(12):2426–2435, August 2021. URL: http://dx.doi.org/10.1002/tox.23355, doi:10.1002/tox.23355. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/tox.23355)

[2. (Chen2021FGD5) Na Chen, Xiangdong Han, Bo Yin, Xue Bai, and Yubin Wang. Fgd5 facilitates tumor growth by regulating egfr ubiquitination in gastric cancer. Biochemical and Biophysical Research Communications, 562:43–49, July 2021. URL: http://dx.doi.org/10.1016/j.bbrc.2021.04.106, doi:10.1016/j.bbrc.2021.04.106. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2021.04.106)

[3. (Valla2017FGD5) Marit Valla, Monica Jernberg Engstrøm, Borgny Ytterhus, Åse Kristin Skain Hansen, Lars Andreas Akslen, Lars Johan Vatten, Signe Opdahl, and Anna Mary Bofin. Fgd5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis. Breast Cancer Research and Treatment, 162(2):243–253, January 2017. URL: http://dx.doi.org/10.1007/s10549-017-4125-8, doi:10.1007/s10549-017-4125-8. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10549-017-4125-8)